Expression of Concern: Potential Risk for Developing Severe COVID-19 Disease Among Anabolic Steroid Users

    February 2021 in “ BMJ case reports ”
    Flavio Cadegiani, Erica Lin, Andy Goren, Carlos Gustavo Wambier
    Studysummary This case study potentially links the use of anabolic steroids to increased severity of COVID-19 in a healthy 28-year-old man, with marked symptom improvement following treatment with proxalutamide.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on casereports.bmj.com →
    Discuss this study in the Community →

    Research cited in this study 12

    1. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial Cureus · 2021
    2. Enzalutamide, a Prostate Cancer Therapeutic, Downregulates TMPRSS2 in Lung and Reduces Cellular Entry of SARS-CoV-2 Research Square (Research Square) · 2021
    3. Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men Journal of The European Academy of Dermatology and Venereology · 2021
    4. Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men Cell Stem Cell · 2020
    5. 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia Journal of The European Academy of Dermatology and Venereology · 2020
    6. Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19 Journal of the European Academy of Dermatology and Venereology · 2020
    7. Male Balding as a Major Risk Factor for Severe COVID-19: A Possible Role for Targeting Androgens and Transmembrane Protease Serine 2 to Protect Vulnerable Individuals Journal of The American Academy of Dermatology · 2020
    8. Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign Journal of The American Academy of Dermatology · 2020
    9. Polycystic Ovary Syndrome (PCOS) and COVID-19: An Overlooked Female Patient Population at Potentially Higher Risk During the COVID-19 Pandemic BMC Medicine · 2020
    10. Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign' Journal of The American Academy of Dermatology · 2020
    11. Androgen Sensitivity Gateway to COVID-19 Disease Severity Drug Development Research · 2020
    12. Emerging Medication for the Treatment of Male Hypogonadism Expert Opinion on Emerging Drugs · 2012